Xiuhua Pan

All Publications

• Self-Adjuvanting Bacteria Hydrogel for SHP1 Checkpoint Inhibition in Tumor-Draining Lymph Nodes to Enhance Cancer Immunotherapy ADVANCED FUNCTIONAL MATERIALS Pan, X., Liu, F., Kang, R., Hu, Z., Pang, Y., Shen, Z., Zhou, X., Zhang, J., Shen, Q. 2024; 34 (51)

  View details for DOI 10.1002/adfm.202409736

  View details for Web of Science ID 001324471500001

• Biomimetic Nanoarchitectonics with Chitosan Nanogels for Collaborative Induction of Ferroptosis and Anticancer Immunity for Cancer Therapy. Advanced healthcare materials Yang, N., Pan, X., Zhou, X., Liu, Z., Yang, J., Zhang, J., Jia, Z., Shen, Q. 2024; 13 (7): e2302752

  Abstract

  Immunogenic cell death (ICD) shows promising therapeutic potential for tumor regression. However, the low sensitivity and immunosuppressive state of current cell death manners seriously impede tumor immunogenicity. Ferroptosis characterized by excessive lipid peroxidation, has emerged as a potential strategy to induce ICD and activate antitumor immune responses. However, the effectiveness of ferroptosis is limited by antioxidant regulatory networks, including the glutathione peroxidase 4 (GPX4) and ferroptosis suppressor protein 1 (FSP1) pathways, presenting challenges for its induction. Herein, they propose a novel approach that involves utilizing functionalized chitosan-ferrocene-sodium alginate (CFA) crosslinked nanogels, which are modified to pravastatin (PRV) and M1 macrophage membrane (MM) (designing as CFA/PRV@MM). Specifically, ferrocene boots intracellular reactive oxygen species levels for efficient glutathione (GSH) depletion through Fenton reaction, thus disrupting the GPX4/GSH axis, while PRV intervenes in the mevalonate pathway to inhibit the FSP1/CoQ10 antioxidant axis, thereby synergistically causing pronounced ferroptotic damage and promoting ICD. The CFA/PRV@MM nanogels demonstrate superior therapeutic efficacy in a mouse breast model, resulting in effective tumor ablation and immune response with minimal side effects. RNA transcription analysis reveals that nanogels can significantly affect metabolic progress, as well as immune activation. This research provides valuable insights into the design of ferroptosis induction for cancer immunotherapy.

  View details for DOI 10.1002/adhm.202302752

  View details for PubMedID 37975280

• Biomimetic bacteria-derived nanoclusters enhance ferroptosis cancer immunotherapy through synergistic CRISPR-photothermo modulation NANO TODAY Pan, X., Yang, J., Kang, R., Zhang, J., Hu, Z., Yang, N., Liu, Z., Jia, Z., Zhou, X., Shen, Q. 2024; 55

  View details for DOI 10.1016/j.nantod.2024.102213

  View details for Web of Science ID 001211243500001

• Reprogramming dysfunctional dendritic cells by a versatile metabolism nano-intervenor for enhancing cancer combinatorial immunotherapy NANO TODAY Yang, J., Pan, X., Zhang, J., Ma, S., Zhou, J., Jia, Z., Wei, Y., Liu, Z., Yang, N., Shen, Q. 2022; 46

  View details for DOI 10.1016/j.nantod.2022.101618

  View details for Web of Science ID 000874233100002

• Applications and developments of gene therapy drug delivery systems for genetic diseases. Asian journal of pharmaceutical sciences Pan, X., Veroniaina, H., Su, N., Sha, K., Jiang, F., Wu, Z., Qi, X. 2021; 16 (6): 687-703

  Abstract

  Genetic diseases seriously threaten human health and have always been one of the refractory conditions facing humanity. Currently, gene therapy drugs such as siRNA, shRNA, antisense oligonucleotide, CRISPR/Cas9 system, plasmid DNA and miRNA have shown great potential in biomedical applications. To avoid the degradation of gene therapy drugs in the body and effectively deliver them to target tissues, cells and organelles, the development of excellent drug delivery vehicles is of utmost importance. Viral vectors are the most widely used delivery vehicles for gene therapy in vivo and in vitro due to their high transfection efficiency and stable transgene expression. With the development of nanotechnology, novel nanocarriers are gradually replacing viral vectors, emerging superior performance. This review mainly illuminates the current widely used gene therapy drugs, summarizes the viral vectors and non-viral vectors that deliver gene therapy drugs, and sums up the application of gene therapy to treat genetic diseases. Additionally, the challenges and opportunities of the field are discussed from the perspective of developing an effective nano-delivery system.

  View details for DOI 10.1016/j.ajps.2021.05.003

  View details for PubMedID 35027949

  View details for PubMedCentralID PMC8737406

• One-in-one individual package and delivery of CRISPR/Cas9 ribonucleoprotein using apoferritin. Journal of controlled release : official journal of the Controlled Release Society Pan, X., Pei, X., Huang, H., Su, N., Wu, Z., Wu, Z., Qi, X. 2021; 337: 686-697

  Abstract

  So far, most reported delivery of CRISPR/Cas9 is achieved by internalized or encapsulated multiple ribonucleoprotein units into only one carrier unit, with relatively large size. Here, we report a novel, small-sized, individual package of CRISPR/Cas9, via using tetralysine modified H-chian apoferritin (TL-HFn) as packaging material. In this paper, each CRISPR/Cas9 complex is proved to be successfully installed into one TL-HFn (~26 nm), and delivered into the targeting cell via TfR1-mediated endocytosis. We found that after 6 h of treatment, the CRISPR/Cas9 complex can be tracked within the nuclear of Hela cells for the purpose of gene editing of enhanced green fluorescent protein (EGFP). Moreover, TL-HFn individually packed CRISPR/Cas9 displayed higher genome editing activity compared with that of free CRISPR/Cas9 treated group both in vitro (up to 28.96%) and in vivo. Such satisfied genome editing efficiency could be attributed to the endosomal escape and pH-induced disassembly abilities given by TL-HFn after uptake into cytoplasm, which had been verified in our previous research. In all, those results prompted that TL-HFn possessed more potential for intracellular delivery of CRISPR/Cas9, with potential biocompatibility, stability and delivery efficiency.

  View details for DOI 10.1016/j.jconrel.2021.08.015

  View details for PubMedID 34389365

• Apoferritin: a potential nanocarrier for cancer imaging and drug delivery. Expert review of anticancer therapy Veroniaina, H., Pan, X., Wu, Z., Qi, X. 2021; 21 (8): 901-913

  Abstract

  Introduction: As a protein-based biomaterial for potential cancer targeting delivery, apoferritin has recently attracted interest.Areas covered: In this review, we discuss the development of this cage-like protein as an endogenous nanocarrier that can hold molecules in its cavity. We present the specific characterizations and formulations of apoferritin nanocarriers, and outline the recent progress of the protein as an appropriate tumor-delivery vehicle in different therapeutic strategies to treat solid tumors. Finally, we propose how the application for cancer drug repurposing delivery within apoferritin could expand cancer treatment in the future.Expert opinion: Being a ubiquitous iron storage protein that exists in many living organisms, apoferritin is promising as a cancer tumor-targeting nanocarrier. By exploiting its versatility, apoferritin could be used for cancer repurposed drug delivery and could reduce the high cost of new drug discovery development and shorten the formulation process.

  View details for DOI 10.1080/14737140.2021.1910027

  View details for PubMedID 33844625

• 4T1 cell membrane fragment reunited PAMAM polymer units disguised as tumor cell clusters for tumor homotypic targeting and anti-metastasis treatment. Biomaterials science Pei, X., Pan, X., Xu, X., Xu, X., Huang, H., Wu, Z., Qi, X. 2021; 9 (4): 1325-1333

  Abstract

  Cell membrane-based nanoparticles have garnered increasing attention owing to their inherent biomimetic properties, such as homotypic targeting, prolong circulation, and immune escaping mechanisms. However, most of these biomimetic nanoparticles appear as an orientated core-shell unit because of the lack of the full utilization and direction control of membranes. Different from those single-unit delivery systems, we reported a multiple-unit nanocluster by randomly reuniting multiple PAMAM polymeric core units into a single nanocluster via simple electrostatic interactions between 4T1 cell membrane fragments and PAMAM. Similar to tumor cell clusters, the doxorubicin (DOX)-loaded nanoclusters (CCNCs) could actively metastasis towards cancer cells after getting access to the systemic circulation due to their specific homotypic targeting ability. In this study, CCNCs showed significantly higher tumor inhibition efficacy in 4T1 tumor-bearing mice compared with that of free DOX and PAMAM@DOX-treated groups. Furthermore, the quantitative analysis showed that the number of pulmonary metastatic nodules remarkably reduced, indicating the potential anti-metastasis effect of CCNCs. Overall, these tumor cell membrane fragment reunited PAMAM polymer units could disguise as tumor cell clusters for encouraging tumor homotypic targeting and anti-metastasis treatment.

  View details for DOI 10.1039/d0bm01731k

  View details for PubMedID 33355563

• Tetralysine modified H-chain apoferritin mediated nucleus delivery of chemotherapy drugs synchronized with passive diffusion JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY Pan, X., Su, N., Li, J., Huang, H., Wu, Z., Sha, K., Chen, J., Wu, Z., Qi, X. 2021; 61

  View details for DOI 10.1016/j.jddst.2020.102132

  View details for Web of Science ID 000619155800003